Skip to content

MiMedx Group MDXG Free cash flow

Free cash flow at other companies

IAR
Integra LifeSciencesIART
-$5.05M+87.4%
Artivion logo
ArtivionAORT
-$6.85M+66.7%
Vericel logo
VericelVCEL
$15.13M+299%
Enovis logo
EnovisENOV
-$28.85M+35.7%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
-$1.16M-3,153%
Solventum logo
SolventumSOLV

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Calculated from MiMedx Group’s reported figures.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's free cash flow?
MiMedx Group (MDXG) reported free cash flow of $1.31M in Q1 2026.
How has MiMedx Group's free cash flow changed year-over-year?
MiMedx Group's free cash flow decreased by 73.4% year-over-year, from $4.92M to $1.31M.
What is the long-term trend for MiMedx Group's free cash flow?
Over 3 years (2022 to 2025), MiMedx Group's free cash flow has grown at a 53.9% compound annual growth rate (CAGR), from -$20.02M to $72.97M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.